Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D’Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin Kaiser, Melissa Ng Liet Hing, Simon J. Harrison, Edward R. Scheffer Cliff, Meera Mohan
{"title":"复发/难治性骨髓瘤患者接受限时双特异性抗体疗法后病情持续缓解","authors":"Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D’Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin Kaiser, Melissa Ng Liet Hing, Simon J. Harrison, Edward R. Scheffer Cliff, Meera Mohan","doi":"10.1038/s41408-024-01114-7","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"2 1","pages":""},"PeriodicalIF":12.9000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma\",\"authors\":\"Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D’Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin Kaiser, Melissa Ng Liet Hing, Simon J. Harrison, Edward R. Scheffer Cliff, Meera Mohan\",\"doi\":\"10.1038/s41408-024-01114-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8989,\"journal\":{\"name\":\"Blood Cancer Journal\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":12.9000,\"publicationDate\":\"2024-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood Cancer Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41408-024-01114-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Cancer Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41408-024-01114-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
期刊介绍:
Blood Cancer Journal is dedicated to publishing high-quality articles related to hematologic malignancies and related disorders. The journal welcomes submissions of original research, reviews, guidelines, and letters that are deemed to have a significant impact in the field. While the journal covers a wide range of topics, it particularly focuses on areas such as:
Preclinical studies of new compounds, especially those that provide mechanistic insights
Clinical trials and observations
Reviews related to new drugs and current management of hematologic malignancies
Novel observations related to new mutations, molecular pathways, and tumor genomics
Blood Cancer Journal offers a forum for expedited publication of novel observations regarding new mutations or altered pathways.